In conclusion, we identify MYT1Lmutations as a cause of syndromic obesity, and establish MYT1L as a member of the leptin-melanocortin-SIM1 pathway, with downstream loss of OXT associated with MYT1L mutations a potential therapeutic target. Here, MYT1L is linked to obesity disorder.